Summary of Kang En Bei's Conference Call Company Overview - **Company**: Kang En Bei - **Industry**: Pharmaceutical Key Financial Metrics - **Revenue**: 4.976 billion CNY in the first three quarters of 2025, a year-on-year increase of 1.72% [2][3] - **Total Profit**: 697 million CNY, up 7.57% year-on-year [2][3] - **Net Profit**: Increased by 12.65%, with a non-recurring net profit growth of 1.6% [2][3] - **Contribution from Jiahe Bio**: 79 million CNY in floating profit, compared to 25.87 million CNY in the same period last year, significantly impacting profit growth [2][3] Product Performance - **Chronic Diarrhea Series**: Over 25% year-on-year growth, attributed to capturing market opportunities from Norovirus, strengthening partnerships with chain pharmacies, stabilizing prices, and enhancing visibility [2][7] - **Jin Di Series**: Declined by 11.6% due to high base effects and a mild flu season [2][6] - **Jin Kang Su Li**: Experienced a 66% decline due to losing bids in centralized procurement [2][6] - **Respiratory Medications**: Some products also saw a decline [2][6] Strategic Goals - **2030 Revenue Target**: 11 billion CNY, with 2 billion CNY from external acquisitions and 9 billion CNY from organic growth [2][8] - **Net Profit Target**: 1 billion CNY, with 200 million CNY from acquisitions and 800 million CNY from organic growth [2][8] - **Management Reforms**: Streamlining management departments from 16 to 11, merging health and sales companies, optimizing distributor structures, and introducing a new executive team to enhance operational quality [2][10] Future Plans - **2026 Revenue Target**: 6.8 billion CNY, with plans to develop multiple brands achieving revenue scales of 500 million to 1 billion CNY [2][11] - **Core Strategy**: Entering the essential drug directory, focusing on products like Execution Dan, Jin Ai Kang, and Long Jin Tong Ling, with expected sales growth rates of over 10% [2][12][13] Challenges and Market Dynamics - **Challenges**: Facing pressure from centralized procurement leading to price reductions, and competition in the pharmaceutical industry [2][6][16] - **Market Opportunities**: Aging population creating unmet medical needs, and the clinical value of traditional Chinese medicine being validated through evidence-based medicine [2][16] R&D and M&A Strategy - **R&D Investment**: Maintaining a 4% investment in R&D, viewing the R&D team as a cost center to foster innovation [2][17] - **M&A Goals**: Aiming for 2 billion CNY in acquisitions by 2030, with ongoing discussions for multiple targets, including overseas projects [2][17] Conclusion - **Overall Performance**: Despite challenges, Kang En Bei has shown resilience with positive growth metrics and a clear strategic direction towards 2030 [2][19] - **Investor Focus**: The company encourages investors to monitor its growth trajectory and strategic initiatives [2][19]